you are here:

Cipla Ltd.

BSE: 500087 | NSE: CIPLA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE059A01026 | SECTOR: Pharmaceuticals

BSE Live

Jun 21, 10:08
952.65 -7.60 (-0.79%)
Volume
AVERAGE VOLUME
5-Day
224,367
10-Day
220,676
30-Day
307,914
25,979
  • Prev. Close

    960.25

  • Open Price

    959.00

  • Bid Price (Qty.)

    952.45 (13)

  • Offer Price (Qty.)

    952.85 (1)

NSE Live

Jun 21, 10:08
952.60 -8.30 (-0.86%)
Volume
AVERAGE VOLUME
5-Day
2,551,808
10-Day
3,079,975
30-Day
5,141,010
394,604
  • Prev. Close

    960.90

  • Open Price

    958.00

  • Bid Price (Qty.)

    952.60 (7)

  • Offer Price (Qty.)

    952.90 (55)

ANNOUNCEMENTS ON Cipla

  • Jun 16, 2021 16:08 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the Operations and Administrative Committee of the Company on 16th June, 2021 has allotted 1,03,359 equity shares of Rs.2/- each pursuant to exercise of the stock options by the option grantees under Employee Stock Option Scheme 2013-A of the Company.

  • Jun 15, 2021 9:35 Source: NSE

    Cipla Limited

    Cipla Limited has informed the Exchange regarding a press release dated Jun 14, 2021, titled "Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol ".

  • Jun 15, 2021 8:55 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

  • Jun 11, 2021 18:54 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the schedule of Analyst / Institutional Investor Meeting with the Company

  • Jun 08, 2021 16:15 Source: BSE

    Cipla - Disclosure Of Related Party Transactions For The Half Year Ended 31St March 2021

    Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards, for the half year ended 31st March, 2021. This disclosure is also being uploaded on the website of the Company i.e. www.cipla.com.

  • Jun 07, 2021 9:42 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the schedule of Analyst / Institutional Investor Meeting with the Company

  • Jun 01, 2021 14:09 Source: BSE

    Cipla - Compliances-Reg.24(A)-Annual Secretarial Compliance

    Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars No. CIR/CFD/CMD1/27/2019 dated February 8, 2019 and No. SEBI /HO /CFD /CMD1 /P/CIR/2021/556 dated April 29, 2021; we are enclosing herewith the Annual Secretarial Compliance Report for the financial year 2020-21 issued by BNP & Associates, Practicing Company Secretaries. This will also be hosted on the Company's website, at www.cipla.com.

  • Jun 01, 2021 7:37 Source: NSE

    Cipla Limited

    Cipla Limited has informed the Exchange regarding ''Response to media query''.

  • Jun 01, 2021 0:14 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that in response to media queries on vaccine distribution, Cipla would be releasing the following statement: "Cipla has been at the forefront of Covid care. We are in the process of seeking clarity & guidance from the Government of India for exploring the possible roadmap for vaccine importation to India. At this stage, no definitive terms have been finalised and hence, the Company cannot comment further.'

  • May 31, 2021 12:38 Source: BSE

    Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the schedule of Analyst / Institutional Investor Meeting with the Company

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : May 14, 2021
Remark : Audited Results & Dividend